Antiandrogen Drugs

Antiandrogen Drugs



Antiandrogen drugs are a diverse group of medications given to counteract the effects of androgens (male sex hormones) on various body organs and tissues. Some medications in this category work by lowering the body's production of androgens while others work by blocking the body's ability to make use of the androgens that are produced. The first group of antiandrogens includes such medications as leuprolide (Lupron, Viadur, or Eligard), goserelin (Zoladex), triptorelin (Trelstar Depot), and abarelix (Plenaxis). The second group includes flutamide (Eulexin), nilutamide (Nilandron), cyproterone acetate (Cyprostat, Androcur, Cyproterone), and bicalutamide (Casodex). Flutamide, nilutamide, and bicalutamide are nonsteroidal antiandrogen drugs while cyproterone acetate is a steroidal medication.
Some drugs that were originally developed to treat other conditions are sometimes categorized as antiandrogens because their off-label uses include some of the disorders listed below. These drugs include medroxyprogesterone (Depo-Provera), a derivative of the female sex hormone progesterone that is used as a contraceptive and treatment for abnormal uterine bleeding; ketoconazole (Nizoral), an antifungal drug; and spironolactone (Aldactone), a diuretic.


Antiandrogen drugs may be given for any of several conditions or disorders, ranging from skin problems to mental disorders:
  • Prostate cancer. Antiandrogen medications may be used to treat both early-stage and advanced prostate cancer by lowering or blocking the supply of male sex hormones that encourage the growth and spread of the cancer.
  • Androgenetic alopecia. Androgenetic alopecia is a type of hair loss that is genetically determined and affects both men and women. It is sometimes called pattern baldness.
  • Acne. Acne is the end result of several factors, one of which is excessive production of sebum, a whitish semiliquid greasy substance produced by certain glands in the skin. Antiandrogens may help to clear acne by slowing down the secretion of sebum, which depends on androgen production.
  • Amenorrhea. Amenorrhea, or the absence of menstrual periods in females of childbearing age, is sometimes caused by excessively high levels of androgens in the blood. Antiandrogen medications may help to restore normal menstrual periods.
  • Hirsutism. Hirsutism is a condition in which women develop excessive facial and body hair in a distribution pattern usually associated with adult males. It results from abnormally high levels of androgens in the bloodstream or from increased sensitivity of the hair follicles to normal levels of androgens. Hirsutism may be a sign of polycystic ovary syndrome (PCOS), a condition in which the ovaries develop multiple large cysts and produce too much androgen.
  • Gender reassignment. Antiandrogen drugs are often prescribed for male-to-female (MTF) transsexuals as part of the hormonal treatment that precedes gender reassignment surgery.
  • Paraphilias. Paraphilias are a group of mental disorders characterized by intense and recurrent sexual urges or behaviors involving nonhuman objects, children or nonconsenting adults, or pain and humiliation. Antiandrogen drugs have been prescribed for men diagnosed with paraphilias in order to lower blood serum levels of testosterone and help them control their sexual urges.
  • Virilization. Virilization is an extreme form of hyperandrogenism in females, marked by such changes as development of male pattern baldness, voice changes, and overdevelopment of the skeletal muscles. Antiandrogens may be given to correct this condition.


  • Leuprolide. Leuprolide is classified as a luteinizing hormone-releasing hormone (LHRH) agonist, which means that it resembles a chemical produced by the hypothalamus (a gland located in the brain) that lowers the level of testosterone in the bloodstream. It also reduces levels of estrogen in girls and women, and may be used to treat endometriosis or tumors in the uterus. It is presently under investigation as a possible treatment for the paraphilias.
  • Goserelin. Goserelin is also an LHRH agonist, and works in the same way as leuprolide.
  • Triptorelin. Triptorelin is an LHRH agonist, and works in the same way as leuprolide. It is not usually given to women, however.
  • Abarelix. Abarelix is a newer drug that works by blocking hormone receptors in the pituitary gland. It is recommended for the treatment of prostate cancer in men with advanced disease who refuse surgery, cannot take other hormonal treatments, or are poor candidates for surgery.
  • Ketoconazole. Ketoconazole is an antifungal drug available in tablets to be taken by mouth. Its use in treating hirsutism is off-label.
  • Flutamide. Flutamide is a nonsteroidal antiandrogen medication that blocks the use of androgen by the body.
  • Nilutamide. Nilutamide is another nonsteroidal antiandrogen drug that works by blocking the body's use of androgens.
  • Bicalutamide. Bicalutamide is a nonsteroidal antiandrogen medication that works in the same way as flutamide.
  • Cyproterone acetate. Cyproterone acetate is a steroidal antiandrogen drug that works by lowering testosterone production as well as blocking the body's use of androgens.
  • Medroxyprogesterone. Medroxyprogesterone is a synthetic derivative of progesterone that prevents ovulation and keeps the lining of the uterus from breaking down, thus preventing uterine bleeding.
  • Spironolactone. Spironolactone is a potassiumsparing diuretic that may be given to treat androgen excess in women.

Recommended dosage

  • Leuprolide. Leuprolide is available in an injectable form and as an implant. The implant form, used to treat prostate cancer, contains 22.5 mg of leuprolide and is inserted under the skin every three months. This type of slow-release medication is called depot form. A longer-acting implant that lasts 12 months is also available. Injectable leuprolide is injected once a day in a 1-mg dose to treat prostate cancer. The dosage for endometriosis or uterine tumors is 3.75 mg injected into a muscle once a month for three to six months.
  • Goserelin. Goserelin is implanted under the skin of the upper abdomen. The dosage for treating cancer of the prostate is one 3.6-mg implant every 28 days or one 10.8-mg implant every 12 weeks. For treating endometriosis, the dosage is one 3.6-mg implant every 28 days for six months.
  • Triptorelin. Triptorelin is given as a long-lasting injection for treatment of prostate cancer or paraphilias. The usual dose for either condition is 3.75 mg, injected into a muscle once a month.
  • Abarelix. Abarelix is given in 100-mg doses by deep injection into the muscles of the buttocks. It is given on days 1, 15, and 29 of treatment, then every four weeks for a total treatment duration of 12 weeks.
  • Ketoconazole. For treatment of hirsutism, 400 mg by mouth once per day.
  • Flutamide. Flutamide is available in capsule as well as tablet form. For treatment of prostate cancer, 250 mg by mouth three times a day. For virilization or hyperandrogenism in women, 250 mg by mouth three times a day. It should be used in women, however, only when other treatments have proved ineffective.
  • Nilutamide. To treat prostate cancer, nilutamide is taken in a single 300-mg daily dose by mouth for the first 30 days of therapy, then a single daily dose of 150 mg.
  • Bicalutamide. Bicalutamide is taken by mouth in a single daily dose of 50 mg to treat prostate cancer.
  • Cyproterone acetate. Cyproterone is taken by mouth three times a day in 100-mg doses to treat prostate cancer. The dose for treating hyperandrogenism or virilization in women is one 50-mg tablet by mouth each day for the first ten days of the menstrual cycle. Cyproterone acetate given to treat acne is usually given in the form of an oral contraceptive (Diane-35) that combines the drug (2 mg) with ethinyl estradiol (35 mg). Diane-35 is also taken as hormonal therapy by MTF transsexuals. The dose for treating paraphilias is 200-400 mg by injection in depot form every 1-2 weeks, or 50-200 mg by mouth daily.
  • Medroxyprogesterone. For the treatment of paraphilias, given as an intramuscular 150-mg injection daily, weekly, or monthly, depending on the patient's serum testosterone levels, or as an oral dose of 100-400 mg daily. As hormonal therapy for MTF transsexuals, 10-40 mg per day. For polycystic ovary syndrome, 10 mg daily for 10 days.
  • Spironolactone. For hyperandrogenism in women, 100-200 mg per day by mouth; for polycystic ovary syndrome, 50-200 mg per day. For the treatment of acne, 200 mg per day. For hormonal therapy for MTF transsexuals, 200-400 mg per day. A topical form of spironolactone is available for the treatment of androgenetic alopecia.


  • Leuprolide. Leuprolide should not be used by pregnant or nursing women, by patients diagnosed with spinal compression, or by patients allergic to the drug. Women taking leuprolide should not try to become pregnant, and should use methods of birth control that do not contain hormones.
  • Goserelin. Goserelin should not be used during pregnancy or lactation, or by patients known to be allergic to it. As with leuprolide, women taking goserelin should use methods of contraception that do not contain hormones.
  • Triptorelin. Patients using triptorelin should see their doctor at regular intervals for monitoring of side effects.
  • Abarelix. Abarelix should not be given to children or women. Because of the severity of this drug's possible side effects, doctors who prescribe it for men must be certified following successful completion of a safety program for its proper use.
  • Ketoconazole. Ketoconazole should not be given to alcoholic patients or those allergic to the drug. In addition, patients using ketoconazole should have their liver function monitored by their doctor.
  • Flutamide. Flutamide should not be used by pregnant women. Patients taking flutamide should have their liver function monitored carefully. They should notify their doctor at once if they have pain in the upper right side of the abdomen or a yellowish discoloration of the eyes and skin, as these are signs of liver damage. In addition, patients using this drug should not discontinue taking it without telling their doctor.
  • Nilutamide. This drug should not be given to patients who are allergic to it, have severe respiratory problems, or have been diagnosed with a liver disorder. Patients taking this drug should discontinue using alcoholic beverages while they are being treated with it.
  • Bicalutamide. The precautions while using this drug are the same as those for flutamide.
  • Cyproterone acetate. This drug has not been approved by the Food and Drug Administration (FDA) for use in the United States, but is approved for use in Canada and the United Kingdom. It should not be used during pregnancy or lactation, or by patients with liver disease. Men who are taking this drug for treatment of paraphilias should not use alcohol.
  • Medroxyprogesterone. This drug should not be given to patients with a history of blood clot formation in their blood vessels. It should be used with caution in patients with asthma, seizure disorders, migraine headaches, liver or kidney disorders, or heart disease.
  • Spironolactone. This drug should not be given to patients with overly high levels of potassium in the blood or to patients with liver disease or kidney failure. It should also not be given to pregnant or lactating women.

Side effects

  • Leuprolide. Side effects of leuprolide in men may include pains in the chest, groin, or legs; hot flashes, loss of interest in sex, or impotence; bone pain; sleep disturbances; and mood changes. Side effects in women may include amenorrhea or light and irregular menstrual periods; loss of bone density; mood changes; burning or itching sensations in the vagina; or pelvic pain.
  • Goserelin. The side effects of goserelin may include nausea and vomiting; they are otherwise the same as for leuprolide.
  • Triptorelin. Side effects of triptorelin include pain in the bladder, difficulty urinating, or bloody or cloudy urine; pain in the side or lower back; hot flashes or headache; loss of interest in sex or impotence; vomiting or diarrhea; unusual bleeding or bruising; pain at the injection site; unusual tiredness or sleep disturbances; depression or rapid mood changes. It may also cause a temporary enlargement of the tumor; this side effect is known as tumor flare.
  • Abarelix. This drug may cause immediate life-threatening allergic reactions following any dose. May also cause a loss of bone mineral density, irregular heartbeat, hot flashes, sleep disturbances, gynecomastia, or pain in the breasts and nipples.
  • Ketoconazole. The side effects of ketoconazole include nausea and vomiting, loss of appetite, abdominal pain, skin rash or itching, uterine bleeding, breast pain, gynecomastia, hair loss, loss of interest in sex, and decline in sperm production.
  • Flutamide. Flutamide has been reported to cause breast tenderness and gynecomastia in men as well as fatigue, nausea, flu-like symptoms, and runny nose; darkened urine; indigestion, constipation, diarrhea, or gas; bluish-colored or dry skin; dizziness; and liver damage. These side effects may be intensified in patients who smoke.
  • Nilutamide. The side effects of nilutamide are the same as those for flutamide. In addition, this drug may affect the ability of the eyes to adjust to sudden changes in light intensity or may make the eyes unusually sensitive to light. Another potential side effect is difficulty breathing; this is more likely to occur in Asian patients taking this drug than in Caucasians.
  • Bicalutamide. The side effects of this drug are the same as those for flutamide.
  • Cyproterone acetate. Cyproterone has been reported to cause gynecomastia, impotence, loss of interest in sex, deep venous thrombosis, and possible damage to the cardiovascular system.
  • Medroxyprogesterone. The side effects of this drug include high blood pressure, headache, nausea and vomiting, changes in menstrual flow, breakthrough bleeding, puffy skin (edema), weight gain, and sore or swollen breasts.
  • Spironolactone. Spironolactone may cause fatigue, headache, and drowsiness; gynecomastia and impotence in men; abdominal cramps, nausea, vomiting, diarrhea, or loss of appetite; and skin rashes or itching.


  • Leuprolide. No interactions with other medications have been reported.
  • Goserelin. No interactions have been reported.
  • Triptorelin. No interactions have been reported.
  • Abarelix. Abarelix may interact with other medications that affect heart rhythm, including procainamide, amiodarone, sotalol, and dofetilde.
  • Ketoconazole. Ketoconazole interacts with a number of drugs, including rifampin, warfarin, phenytoin, antacids, cyclosporine, terfenadine, and astemizole. It may cause a sunburn-like skin reaction if used together with alcohol.
  • Flutamide. This drug has been reported to intensify the effects of warfarin (Coumadin) and other blood-thinning medications. It has also been reported to intensify the effects of phenytoin (Dilantin), a drug given to control seizures.
  • Nilutamide. Reported interactions are the same as for flutamide; in addition, nilutamide has been reported to intensify the effects of theophylline (Theo-Dur), a drug given to treat asthma.
  • Bicalutamide. Reported interactions are the same as for flutamide.
  • Cyproterone acetate. Patients taking oral medications to control diabetes may require dosage adjustments while taking this drug.
  • Medroxyprogesterone. Patients taking phenobarbital, phenothiazine tranquilizers (chlorpromazine, perphenazine, fluphenazine, etc.), or oral medications to control diabetes should consult their doctor about dosage adjustments.
  • Spironolactone. Spironolactone is reported to decrease the effectiveness of aspirin and anticoagulants (blood thinners). It may also interact with potassium supplements to increase the patient's blood potassium level.



"Amenorrhea." Section 18, Chapter 235 in The Merck Manual of Diagnosis and Therapy, edited by Mark H. Beers, MD, and Robert Berkow, MD. Whitehouse Station, NJ: Merck Research Laboratories, 2005.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association, 2000.
"Paraphilias." Section 15, Chapter 192 in The Merck Manual of Diagnosis and Therapy, edited by Mark H. Beers, MD, and Robert Berkow, MD. Whitehouse Station, NJ: Merck Research Laboratories, 2005.
"Prostate Cancer." Section 17, Chapter 233 in The Merck Manual of Diagnosis and Therapy, edited by Mark H. Beers, MD, and Robert Berkow, MD. Whitehouse Station, NJ: Merck Research Laboratories, 2005.


Bradford, J. M. "The Neurobiology, Neuropharmacology, and Pharmacological Treatment of the Paraphilias and Compulsive Sexual Behavior." Canadian Journal of Psychiatry 46 (February 2001): 26-34.
Brannon, Guy E., MD. "Paraphilias." eMedicine, 17 October 2002.
Feinstein, Robert, MD. "Androgenetic Alopecia." eMedicine, 2 October 2003.
Harper, Julie C., MD, and James Fulton, Jr., MD. "Acne Vulgaris." eMedicine, 29 July 2004. 〈〉.
Hunter, Melissa H., MD, and Peter J. Carek, MD. "Evaluation and Treatment of Women with Hirsutism." American Family Physician 67 (June 15, 2003): 2565-2572.
Hyperandrogenic Disorders Task Force. "American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hyperandrogenic Disorders." Endocrine Practice 7 (March-April 2001): 120-135.
Krueger, R. B., and M. S. Kaplan. "Depot-Leuprolide Acetate for Treatment of Paraphilias: A Report of Twelve Cases." Archives of Sexual Behavior 30 (August 2001): 409-422.
Oriel, Kathleen A., MD, MS. "Medical Care of Transsexual Patients." Journal of the Gay and Lesbian Medical Association 4 (April 2000): 185-194.
Patel, Vipul, MD, and Raymond J. Leveille, MD. "Prostate Cancer: Neoadjuvant Androgen Deprivation." eMedicine, 10 March 2005.
Richardson, Marilyn R., MD. "Current Perspectives in Polycystic Ovary Syndrome." American Family Physician 68 (August 15, 2003): 697-704.
Thorneycroft, Ian, MD, PhD. "Androgen Excess." eMedicine, 28 February 2004. 〈〉.


American Academy of Dermatology (AAD). P. O. Box 4014, Schaumburg, IL 60168-4014. (847) 330-0230. Fax: (847) 330-0050.
American Association of Clinical Endocrinologists (AACE). 1000 Riverside Avenue, Suite 205, Jacksonville, FL 32204. (904) 353-7878. Fax: (904) 353-8185.
American Psychiatric Association (APA). 1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901. (800) 368-5777 or (703) 907-7322. Fax: (703) 907-1091.
Harry Benjamin International Gender Dysphoria Association, Inc. (HBIGDA). 1300 South Second Street, Suite 180, Minneapolis, MN 55454. (612) 624-9397. Fax: (612) 624-9541.
National Cancer Institute (NCI). NCI Public Inquiries Office, Suite 3036A, 6116 Executive Boulevard, MSC8332, Bethesda, MD 20892-8322. (800) 4-CANCER or (800) 332-8615 (TTY).
National Institute of Mental Health (NIMH). 6001 Executive Boulevard, Room 8184, MSC 9663, Bethesda, MD 20892-9663. (301) 443-4513 or (886) 615-NIMH.
United States Food and Drug Administration (FDA). 5600 Fishers Lane, Rockville, MD 20857-0001. (888) INFO-FDA.


National Cancer Institute (NCI). Prostate Cancer (PDQ®): Treatment, Health Professional version.
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
"When you're giving antiandrogen drugs, you should probably monitor for torsade de pointes and be very careful about controlling the other risk factors for QT prolongation," Salem said.
Finally, the doctor may prescribe an antiandrogen drug, such as spironolactone, which helps prevent androgens from causing excessive oil production.